PSMG3

Across TCGA pan-cancer cohorts, PSMG3 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated PSMG3 data layer compared with 26 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher PSMG3 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated PSMG3 expression acts as an unfavorable survival marker, although some lineages such as LSCC and OV show a favorable association.

LUAD, GBM, and PDAC are the cancer types where PSMG3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Median	II,III,IV	0.343	0.639	.009	25	view →
GBM	OS	Median	All	0.266	0.502	.010	11	view →
PDAC	DFS	Tertile	IV	0.205	0.752	.024	8	view →
LSCC	DFS	Median	II,III,IV	0.843	0.558	.005	5	view →
OV	DFS	Median	All	1.000	0.861	.048	4	view →
HNSC	DFS	Median	IV	0.903	0.695	.013	4	view →
CCRCC	OS	Median	All	1.000	0.911	.023	3	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

PSMG3–LUAD (DFS)

Open the LUAD breakdown →